Making Biotherapeutics Affordable by Advanced Science and Technology

ArtiaBio is a dynamic company specialized on the development of biopharmaceuticals. Our advanced technology in cell line and process development combined with the utilization of advanced bioprocess technology allow development of highly effective manufacturing processes that can provide the biotechnology-based drugs at an affordable price. We have experience and expertise in a broad range of products, including monoclonal antibodies, blood coagulation factors, therapeutic enzymes, and fusion proteins.

ArtiaBio has several parental cell lines, highly productive expression vectors, and owns proprietary media and feeds that yield very excellent productivities in fed-batch and continuous (perfusion).

Our proprietary platform can be applied to novel therapeutic products, biosimilars, and biobetters

We are specialized in both fed-batch and continuous perfusion and we have expertise with several cell line platforms (CHO, NS0, Sp2/0).

Recombinant DNA Technology

Genetic engineering of mammalian cells using recombinant DNA technology has delivered a new class of medicines that provided safe and effective treatments in the fields of cancer, immunology, dermatology and has resulted in multi-billion dollar industry. Major pharmaceutical companies like Roche/Genentech, Amgen, Janssen, Merck, Pfizer, Biogen, and many other companies have produced medicines that have helped patients for many years.

Pasted Graphic